期刊
JOURNAL OF MATERIALS CHEMISTRY B
卷 6, 期 42, 页码 6705-6722出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c8tb02020e
关键词
-
资金
- Juvenile Diabetes Research Foundation (JDRF)
- Hartwell Foundation
- Novo Nordisk Company
This review focuses on recent engineering advances in islet encapsulation technologies. beta-cell replacement therapy in the form of allogeneic naked islet transplantation has become an established treatment for type 1 diabetes mellitus (T1DM). However, some limitations still impact the broad applicability and long-term efficacy of the procedure, including shortage of donor islets, the need for lifelong immunosuppression, and restriction to the most vulnerable patients. Islet encapsulation promises to overcome these constraints by providing a selectively permeable barrier between host and therapeutic tissues. While tremendous progress has been made and the clearing of key translational hurdles appears to be near, many challenges need to be addressed before this technology platform can enter the clinic. Here, we summarize the research in this area and seek to identify the outstanding challenges in translating islet encapsulation technology to human patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据